Hypertension Clinical Trial
— SPPAOfficial title:
A Multicenter, Assessor-blinded, Controlled, Randomised, Parallel Group, Superiority, Pragmatic Trial Assessing the Effectiveness of Daily SMS-reminders in Pharmaceutical Care of Older Adults With Hypertension on Improving Patients' Adherence to Blood Pressure-lowering Medication
Verified date | February 2018 |
Source | Comenius University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
By conducting the SPPA trial we try to find out, whether personalized Short Message Service (SMS) reminders of blood pressure-lowering medication can effectively increase patients' adherence to blood pressure-lowering medication. Additionally, we also evaluate their effect on patients' systolic blood pressure control.
Status | Completed |
Enrollment | 300 |
Est. completion date | February 14, 2018 |
Est. primary completion date | January 10, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years and older |
Eligibility |
Inclusion Criteria: - Age = 55 years (from the day of the 55. birthday inclusive) - Diagnosis of primary (essential) hypertension (I10 according to International Classification of Diseases (ICD-10)) - Filling of blood pressure-lowering prescription(s) at trial recruitment (Visit 1) - Duration of antihypertensive drug treatment for at least 1 year without any discontinuation - Ownership of a mobile phone for personal use with the ability to open and read SMS - Understanding of Slovak language on native-speaker level - Informed consent for participation in the clinical trial and personally signed Informed Consent Form Exclusion Criteria: Exclusion criteria assessed prior to patient enrolment (by trial pharmacists): - Planned hospitalisation during the trial period (3 months) - Biological impairment affecting the ability to read the SMS (e.g. loss of vision, visual field cuts, aphasia) - Living in the same household with another trial participant - Participation in another clinical trial Exclusion criteria assessed after patient enrolment (by trial pharmacists and project leader): - Hospitalisation during the trial period - Patient informs he/she won't be able to participate in the trial - Withdrawal of Informed Consent |
Country | Name | City | State |
---|---|---|---|
Slovakia | Lekáren Bernolákova, Dr. Max | Žilina | |
Slovakia | Lekáren Needham | Banská Bystrica | |
Slovakia | Lekáren V KAUFLANDE BB, s.r.o. | Banská Bystrica | |
Slovakia | Lekáren DANUBIA | Bratislava | |
Slovakia | Lekáren Dr.Max 12 | Bratislava | |
Slovakia | Lekáren Poliklinika Šustekova | Bratislava | |
Slovakia | Lekáren GREEN-STRAP | Dubnica nad Váhom | |
Slovakia | Lekáren Námestie Matice Slovenskej, Dr. Max | Dubnica nad Váhom | |
Slovakia | Lekáren Dr.Max 90, Nemocnica s poliklinkou Sv.Lukáša | Galanta | |
Slovakia | Lekáren REDMOON | Hnúšta | |
Slovakia | Lekáren 17 | Kežmarok | |
Slovakia | Lekáren Námestie Osloboditelov, Dr. Max | Liptovský Mikuláš | |
Slovakia | Lekáren RED-MARKET s.r.o. | Malacky | |
Slovakia | Lekáren PRED NEMOCNICOU | Martin | |
Slovakia | Lekáren, OC Tulip | Martin | |
Slovakia | Lekáren Námestie Slobody, Dr. Max | Pieštany | |
Slovakia | Lekáren HEALTHSTORE | Prešov | |
Slovakia | Lekáren Dr.Max 22 | Rimavská Sobota | |
Slovakia | Lekáren Dr.Max 36 | Rožnava | |
Slovakia | Lekáren OC Madaras Dr. Max | Spišská Nová Ves | |
Slovakia | Lekáren EURO FARMÁCIA s.r.o. | Trencín | |
Slovakia | Lekáren SD5 s.r.o. | Trencín | |
Slovakia | Lekáren CASTILION | Vranov nad Toplou | |
Slovakia | Železnicná Lekáren | Zvolen |
Lead Sponsor | Collaborator |
---|---|
Comenius University | Dr. Max Pharmacies, Research Institute for Child Psychology and Pathopsychology, University of California, Los Angeles |
Slovakia,
Haramiova Z, Stasko M, Hulin M, Tesar T, Kuzelova M, Morisky DM. The effectiveness of daily SMS reminders in pharmaceutical care of older adults on improving patients' adherence to antihypertensive medication (SPPA): study protocol for a randomized controlled trial. Trials. 2017 Jul 18;18(1):334. doi: 10.1186/s13063-017-2063-8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Overall direct treatment costs | Direct treatment costs (monthly average) of blood pressure-lowering medication for each patient will be assessed according to the List of categorized drugs issued by the Ministry of Health of the Slovak Republic. | at Visit 2 (at follow-up visit; 3 months after Visit 1) | |
Other | Signals of adverse events associated with blood pressure-lowering medication | During the whole course of the trial we will actively seek for signals of adverse events associated with blood pressure-lowering medication. Patients will have te possibility to report them any time during the trial. Additionally, trial pharmacists will specifically ask the patients about any potential signals of adverse events at Visit 2. | at Visit 2 (at follow-up visit; 3 months after Visit 1) | |
Other | Number of patients who refused to participate in the study (Patients Refusal Rate) | We will collect the number of patients who refused to participate in the study and report it as percentage of the overall approached patients. | Trough enrollment | |
Other | Number of participants who withdrew from the study (Participants Withdrawal Rate) | We will collect the number of patients who withdrew from the study (early study termination) and report it as percentage of the overall study participants. Also, anonymous reasons for withdrawal from study will be collected, if the patients wish to provide such information. | From date of randomization until Visit 2 (3 months after Visit 1) or the date of early study termination, whichever came first, assessed up to 3 months | |
Primary | Combined adherence endpoint | Measurement variable: adherence status (dichotomous) assessed via the eight item Morisky Medication Score (MMAS-8) as follows: adherent: MMAS-8 score =6 and pill count rate =80% or <=120% non-adherent: MMAS-8 score <6 and/or pill count rate <80% or >120% Analysis Metric: final value (Visit 2) Method of aggregation: proportion of adherent patients (%) |
at Visit 2 (follow-up visit after 3 months of intervention period) | |
Secondary | Change in medians of MMAS-8 after 3 months | Specific measurement variable: MMAS-8 (categorical, ordinal) Analysis Metric: change from baseline (Visit 1) Method of aggregation: median | at Visit 2 (at follow-up visit; 3 months after Visit 1) | |
Secondary | Mean Adherence Rate (%) after 3 months calculated via pill count | Specific measurement variable: adherence rate (%), continuous variable Analysis Metric: final value (at Visit 2) Method of aggregation: mean | at Visit 2 (at follow-up visit; 3 months after Visit 1) | |
Secondary | Mean change in systolic BP after 3 months | Specific measurement variable: systolic blood pressure in mmHg (continuous variable) Analysis Metric:change from baseline (Visit 1) Method of aggregation: mean | at Visit 2 (at follow-up visit; 3 months after Visit 1) | |
Secondary | Patients' satisfaction with SMS reminders. | Patient satisfaction will be assessed using a Satisfaction Questionnaire based on previous studies. | at Visit 2 (at follow-up visit; 3 months after Visit 1) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |